RJA
CANF

Raymond James & Associates’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Raymond James & Associates’s Portfolio CANF Stock Details CANF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5
Closed -$12K – 3654
2019
Q1 		$12K Hold
5
– – ﹤0.01% 3560
2018
Q4 		$17K Hold
5
– – ﹤0.01% 3445
2018
Q3 		$18K Hold
5
– – ﹤0.01% 3545
2018
Q2 		$16K Hold
5
– – ﹤0.01% 3507
2018
Q1 		$20K Buy
5
+1
+25% +$5.52K ﹤0.01% 3381
2017
Q4 		$18K Hold
4
– – ﹤0.01% 3350
2017
Q3 		$21K Hold
4
– – ﹤0.01% 3309
2017
Q2 		$22K Buy
+4
New +$22K ﹤0.01% 3252

Other funds holding CANF

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return

Raymond James & Associates's CANF Position: Q2 2019 in Review

Raymond James & Associates sold out of Can-Fite BioPharma American Depositary Shares (CANF) in Q2 2019, closing a stake of 5 shares — an estimated $12K sold.

Raymond James & Associates first reported a position in CANF in Q2 2017 and held it in 8 quarters. The position peaked at $22K in Q2 2017. 6 funds tracked by Wall St. Rank hold CANF as of Q2 2019.

  • Raymond James & Associates reported no remaining Can-Fite BioPharma American Depositary Shares position as of Q2 2019 after selling out during the quarter.
  • Raymond James & Associates sold 5 Can-Fite BioPharma American Depositary Shares shares in Q2 2019, an estimated $12K.
  • Raymond James & Associates first reported a position in Can-Fite BioPharma American Depositary Shares in Q2 2017 and held it in 8 quarters.
  • Raymond James & Associates's Can-Fite BioPharma American Depositary Shares position peaked at $22K in Q2 2017.
  • 6 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q2 2019.

Based on Raymond James & Associates's 13F filing for Q2 2019, filed 6 Aug 2019.